Affimed N.Vの時価総額
Affimed N.Vの時価総額は何ですか。
Affimed N.V.の時価総額は176.22M$です。
時価総額の定義は何ですか。
時価総額は、取引された会社の発行済株式の市場価値であり、一定期間のb株式に発行済株式数を掛けたものに等しい。
As outstanding stock is bought and sold in public markets, capitalization could be used as an indicator of public opinion of a company's net worth and is a determining factor in some forms of stock valuation.
Market capitalization is used by the investment community in ranking the size of companies, as opposed to sales or total asset figures. It is also used in ranking the relative size of stock exchanges, being a measure of the sum of the market capitalizations of all companies listed on each stock exchange. In performing such rankings, the market capitalizations are calculated at some significant date, such as 30 June or 31 December.
The total capitalization of stock markets or economic regions may be compared with other economic indicators. The total market capitalization of all publicly traded companies in the world was US$51.2 trillion in January 2007 and rose as high as US$57.5 trillion in May 2008 before dropping below US$50 trillion in August 2008 and slightly above US$40 trillion in September 2008. In 2014 and 2015, global market capitalization was US$68 trillion and US$67 trillion, respectively.
NASDAQのセクタHealth Careにおける時価総額の企業と比べるAffimed N.V
Affimed N.Vは何をしますか。
affimed (symbol: afmd) is a nasdaq-listed clinical-stage biopharmaceutical company focused on discovering and developing targeted immuno-oncology therapies. immuno-oncology represents a highly promising approach to cancer treatment that seeks to harness the body’s own immune defenses to attack and destroy tumor cells. natural killer cells, or nk-cells, and t-cells belong to the most potent cells of the human defense arsenal. affimed’s proprietary, next-generation bispecific antibodies, termed tandabs®, are designed to bring nk-cells or t-cells into close proximity to cancer cells that ultimately triggers a signal cascade that leads to the destruction of cancer cells. due to their novel tetravalent tandem architecture, which provides for four binding domains, the tandabs bind to specific targets on immune and cancer cells with high affinity. in addition, tandabs exhibit kinetic properties allowing the administration as regular intravenous infusion and fine-tuning of dosing. affimed beli
Affimed N.Vと類似の時価総額
- Arix Bioscience plcの時価総額は176.05M$です。
- AVITA Therapeuticsの時価総額は176.07M$です。
- Temple Bar Investment Trust Plcの時価総額は176.11M$です。
- ResApp Healthの時価総額は176.14M$です。
- Vidler Water Resources Incの時価総額は176.18M$です。
- Kamada Ltdの時価総額は176.19M$です。
- Affimed N.Vの時価総額は176.22M$です。
- Inventiva SAの時価総額は176.26M$です。
- Cheuk Nang ()の時価総額は176.27M$です。
- Mobius Investment Trust Plcの時価総額は176.28M$です。
- Yangzhou Guangling District Taihe Rural Micro-financeの時価総額は176.56M$です。
- Mortgage Choiceの時価総額は176.64M$です。
- EcoSynthetixの時価総額は176.83M$です。